On the strategy of using nonviral carriers in cancer gene therapy.

A Sochanik; S Szala

doi:10.18388/abp.1996_4497

On the strategy of using nonviral carriers in cancer gene therapy.

A Sochanik Institute of Oncology, Department of Tumor Biology, Gliwice, Poland.;
S Szala

DOI: https://doi.org/10.18388/abp.1996_4497

Abstract

Effectiveness and mode of therapeutic gene delivery in vivo as well as biological safety of such transfer must be improved before widespread application of gene therapy in the clinic becomes possible. Most research has so far focused on recombinant viral delivery systems. Clinical future seems to belong, however, to nonviral delivery systems. Such systems feature DNA complexed to lipid, protein, peptide or polymeric carriers with ligands allowing in vivo tissue targeting by the complex and nuclear translocation of the exogene. Nonviral gene carrier systems are discussed together with strategies of destroying cancer cells.

Published

1996-06-30

Issue

Vol. 43 No. 2 (1996)

Section

Articles

Acta Biochimica Polonica is an OpenAccess quarterly and publishes four issues a year. All contents are distributed under the Creative Commons Attribution-ShareAlike 4.0 International (CC BY 4.0) license. Everybody may use the content following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.